A Phase 1 interventional study of DP-QB-MYA-002 in Mycobacterium Abscessus Infection, Bacteriophage Therapy and Pulmonary Disease, sponsored by Alberta Health services. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-24.
Sponsored by Alberta Health services · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this study is to evaluate mycobacteriophage therapy using in-vitro validated mycobacteriophage DP-QB-MYA-002 in combination with conventional antimycobacterial agents for the treatment of multidrug-resistant Mycobacterium abscessus pulmonary disease, with the goal of reducing mycobacterial burden and improving pulmonary outcomes.
54 studies on the registry are indexed under Mycobacterium Infections, Nontuberculous; 19 are open to participants now.
This study's planned enrollment of 1 is below the median of 40 across 35 interventional studies indexed under Mycobacterium Infections, Nontuberculous.
Browse Mycobacterium Infections, Nontuberculous studies →Alberta Health services is the lead sponsor of 40 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Use of Mycobacteriophage
Biological: DP-QB-MYA-002
In-vitro effective Mycobacteriophage DP-QB-MYA-002 against specific strain of Mycobacterium abscessus ssp abscessuss
Time to Sputum Culture Conversion (Microbiologic Response)
Serial AFB smear grading and serial mycobacterial sputum cultures during and post treatment
Time frame: 1 year
Change in Volume of Sputum Production (Clinical Response)
Patient Report
Time frame: 1 year
Change in frequency of Cough (Clinical Response)
Patient Report
Time frame: 1 year
Change in FEV1 (Clinical Response)
This will be assessed via spirometry at baseline and at the end of the study An increase in FEV1 indicating improvement in lung function or FEV1 decrease indicating decline in lung function.
Time frame: 1 year
Change in BMI (Clinical Response)
Within subject change in BMI measured in kg/m\^2. Increase in BMI as a sign of improvement. Decline in BMI as sign of decline or worse outcome.
Time frame: 1 year
Radiographic Response
Chest imaging response (CT scan) to treatment. Reduction in size, number or density of pulmonary nodules indicating improvement, whereas increased size, number or density indicating worsening.
Time frame: 1 year
Adverse Effects (Clinical)
Adverse clinical and laboratory events (number and severity) on treatment
Time frame: 1 year
No study locations are listed for this record.
Start is estimated for Jul 2026; primary completion for Jul 2027, 12 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mycobacterium Infections, Nontuberculous →
Alberta Health services